EYPT Live signals | Maximize Profits with Getagraph.com

SELL 102148 min ago

@ $29.50

Issued: 14 Feb 2024 @ 15:25

Return: -45.59%

Previous signal: Feb 14 - 13:36

Previous signal: Buy

Return: 0.61 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 14:53):

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom...

Stats
Today's Volume	474 445
Average Volume	998 656
Market Cap	799.78M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-0.340 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.82
ATR14	$0.0250 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Adage Capital Management, L.p.	Buy	0	Common Stock, par value $0.001 per share ("Common Stock")
2024-04-18	Cormorant Asset Management, Lp	Buy	186 521	Common Stock
2024-04-18	Cormorant Asset Management, Lp	Buy	395 244	Common Stock
2024-03-30	Paggiarino Dario A.	Buy	14 000	Common Stock
2024-03-30	Paggiarino Dario A.	Buy	30 570	Common Stock

INSIDER POWER
41.04
Last 98 transactions
Buy: 1 049 923 \| Sell: 467 144

Volume Correlation

Long: 0.31 (neutral)

Short: -0.75 (moderate negative)

Signal:(49.608) Neutral

EyePoint Pharmaceuticals Correlation

10 Most Positive Correlations
TLGT	0.838
RMRM	0.83
CMLF	0.818
AGNG	0.817
FEYE	0.817
SVAC	0.813
ELDN	0.807
GLPG	0.803

10 Most Negative Correlations
AMRB	-0.874
MMAC	-0.863
OZK	-0.841
RDI	-0.84
PLUS	-0.83
RBCAA	-0.829
ISPC	-0.808
III	-0.807
PLL	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

EyePoint Pharmaceuticals Correlation - Currency/Commodity

-0.32
( neutral )

-0.33
( neutral )

0.00
( neutral )

-0.31
( neutral )

0.31
( neutral )

-0.29
( neutral )

EyePoint Pharmaceuticals Financials

Annual	2023
Revenue:	$46.02M
Gross Profit:	$41.39M (89.93 %)
EPS:	$-1.820

Q4	2023
Revenue:	$14.03M
Gross Profit:	$13.03M (92.89 %)
EPS:	$-0.330

Q3	2023
Revenue:	$15.20M
Gross Profit:	$14.00M (92.09 %)
EPS:	$-0.330

Q2	2023
Revenue:	$9.11M
Gross Profit:	$7.31M (80.32 %)
EPS:	$-0.610

Financial Reports:

No articles found.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.